Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain.
Adv Ther
; 41(9): 3569-3584, 2024 Sep.
Article
em En
| MEDLINE
| ID: mdl-39039388
ABSTRACT
INTRODUCTION:
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for glycemic control, with many also demonstrating cardiovascular (CV) benefit, in people with type 2 diabetes (T2D). This study aimed to find a consensus on the barriers and strategies for the optimal use of GLP-1 RAs in people with T2D and high CV risk or established cardiovascular disease (CVD) in Spain.METHODS:
A two-round Delphi survey (53 questions) was conducted among members of four national scientific societies in Spain, including physicians experienced in the management of people with T2D. The degree of consensus was evaluated with a 7-point Likert scale, establishing consensus when ≥ 70% of the panelists agreed (6-7) or disagreed (1-2).RESULTS:
A total of 97 physicians participated in the first round (endocrinology 34%, family and community medicine 21%, internal medicine 23%, and cardiology 23%), and 96 in the second round. The main barriers identified were therapeutic inertia and late use of GLP-1 RAs; lack of a comprehensive approach to CV risk; lack of knowledge on the usefulness of GLP-1 RAs in CVD prevention and treatment; and economic/administrative barriers. Strategies with a highest consensus included the need to establish simple protocols that integrate awareness of CV risk monitoring; training professionals and patients; and the use of new technologies.CONCLUSION:
Physicians identified clinical, healthcare, and economic/administrative barriers that limit the use of GLP-1 RAs in people with T2D and high CV risk or established CVD in Spain, highlighting the importance of integrating these therapies according to clinical practice guidelines.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doenças Cardiovasculares
/
Técnica Delphi
/
Diabetes Mellitus Tipo 2
/
Receptor do Peptídeo Semelhante ao Glucagon 1
/
Hipoglicemiantes
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article